Literature DB >> 24297812

Ocular onchocerciasis in the Yanomami communities from Brazilian Amazon: effects on intraocular pressure.

Guilherme Herzog-Neto1, Karen Jaegger, Erika S do Nascimento, Verônica Marchon-Silva, Dalma M Banic, Marilza Maia-Herzog.   

Abstract

To determine the influence of onchocercal eye disease on the intraocular pressure of the Yanomami Tribe Aratha-ú of Roraima State, Brazil, considered endemic for onchocerciasis, a total of 86 patients were submitted to an ophthalmologic exam that included external examination, slit lamp examination, intraocular pressure measurement, and a fundus ophthalmoscope examination. A high prevalence of onchocerciasis-related eye lesions was encountered in 68.6% of the patients. Punctate keratitis and microfilariae in the anterior chamber were found in ∼28%. The mean of intraocular eye pressure found was 10.47 mm of Hg.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24297812      PMCID: PMC3886435          DOI: 10.4269/ajtmh.13-0357

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  The reliability of anterior segment lesions as indicators of onchocercal eye disease in Guatemala.

Authors:  Kevin L Winthrop; Roberto Proaño; Orlando Oliva; Byron Arana; Carlos Mendoza; Alfredo Dominguez; Josef Amann; George Punkosdy; Carlos Blanco; Robert Klein; Mauricio Sauerbrey; Frank Richards
Journal:  Am J Trop Med Hyg       Date:  2006-12       Impact factor: 2.345

2.  Onchocerciasis: a potential risk factor for glaucoma.

Authors:  P R Egbert; D W Jacobson; S Fiadoyor; P Dadzie; K D Ellingson
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

Review 3.  Pathogenesis of onchocercal keratitis (River blindness).

Authors:  L R Hall; E Pearlman
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

4.  Regulatory effects of Th1-type (IFN-gamma, IL-12) and Th2-type cytokines (IL-10, IL-13) on parasite-specific cellular responsiveness in Onchocerca volvulus-infected humans and exposed endemic controls.

Authors:  P T Soboslay; C G Lüder; S Riesch; S M Geiger; M Banla; E Batchassi; A Stadler; H Schulz-Key
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

5.  Changing views on open-angle glaucoma: definitions and prevalences--The Rotterdam Study.

Authors:  R C Wolfs; P H Borger; R S Ramrattan; C C Klaver; C A Hulsman; A Hofman; J R Vingerling; R A Hitchings; P T de Jong
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

6.  Identification of a gene that causes primary open angle glaucoma.

Authors:  E M Stone; J H Fingert; W L Alward; T D Nguyen; J R Polansky; S L Sunden; D Nishimura; A F Clark; A Nystuen; B E Nichols; D A Mackey; R Ritch; J W Kalenak; E R Craven; V C Sheffield
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

7.  Socioeconomic consequences of blinding onchocerciasis in west Africa.

Authors:  T G Evans
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

8.  [Central and peripheral corneal thickness: influence on the iop measurement by Tonopen].

Authors:  Willer Otávio Guimarães Amaral; Roberto Márcio Batista Teixeira; Leandro Moulin Alencar; Sebastião Cronemberger; Nassim Calixto
Journal:  Arq Bras Oftalmol       Date:  2006-02-10       Impact factor: 0.872

9.  The aging effect on intraocular pressure in an apparently normal population.

Authors:  Y Shiose
Journal:  Arch Ophthalmol       Date:  1984-06

10.  Progress toward elimination of onchocerciasis in the Americas - 1993-2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-05-24       Impact factor: 17.586

View more
  1 in total

1.  A new methodology for sampling blackflies for the entomological surveillance of onchocerciasis in Brazil.

Authors:  Érika S do Nascimento-Carvalho; Raquel de Andrade Cesário; Vladimir Fazito do Vale; Arion Tulio Aranda; Ana Carolina Dos Santos Valente; Marilza Maia-Herzog
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.